Register now!

The use of convalescent plasma collected from previously infected individuals to passively transfer antibodies in order to protect or treat humans dates back almost 100 years, with some evidence for benefit against rabies, hepatitis B, polio, measles, influenza, Ebola, and other pathogens. Today, convalescent plasma could provide short-medium term humoral immunity against COVID-19. The use of convalescent plasma is an interim approach while vaccines and effective drug therapies are being developed. While the concept is simple, numerous steps are involved, and require cooperation between multiple entities, such as recovered patients who serve as donors; blood centers or other plasma collection centers; treating physicians and their patients; and health care administrators and regulators overseeing the safety of each step.

Register and join us tomorrow, May 12, at 6:00 p.m. Eastern time, to learn about the collection of, regulation of, and treatment with convalescent plasma. We anticipate significant interest in this webinar, so we encourage you to register in advance. We will also share the webinar recording with all those who register.



Chancellor Donald, MD
Assistant Professor of Medicine, Tulane University
Chair, ASH Committee on Practice


Peter Marks, MD, PhD
Director, Center for Biologics Evaluation and Research (CBER)
U.S. Food and Drug Administration (FDA)

Beth Shaz, MD
Executive Vice President and Chief Medical and Scientific Officer, New York Blood Center
President, AABB

Evan Bloch, MD, MS
Associate Professor of Pathology and Associate Director of Transfusion Medicine, Johns Hopkins University School of Medicine